

**MEDIA RELEASE • COMMUNIQUE AUX MEDIAS • MEDIENMITTEILUNG**

## **Novartis introduces pioneering equal parental leave policy in South Africa**

- **Novartis parents to enjoy equal parental leave benefits regardless of gender**

**Johannesburg, South Africa – 1 July 2019:** Novartis South Africa today became one of the first countries that launched its global equal parental leave policy as part of its commitment to celebrating the life-changing importance of becoming a parent.

The ground-breaking move will give all new parents paid parental leave of a minimum of 14 weeks (three and a-half months) following the birth, surrogacy or adoption of a child. “The policy serves as a symbol of equality for all new parents in Novartis, allowing our people to revel in one of life’s most special events and spend time bonding with their new babies and families.

“Essentially, this means giving new Novartis parents the means to help them enjoy greater flexibility and financial stability during one of the most important time of their lives,” says Mo Kadwa, CEO at Novartis South Africa.

Egypt, Germany, India, Mexico and Switzerland join South Africa as the countries that the policy has been introduced in as part of Phase I, while Phases II and III of the equal parental leave policy will be rolled out in additional Novartis markets from January 2020 and 2021 respectively

According to the Labour Relations and Labour Amendment Act of South Africa that was signed into law in November 2018, working South African new dads became entitled to 10 days of paternity leave after the birth of their children. The Act also includes provision for 10 weeks of parental adoption leave if the child is aged below two but applies to one parent only, surrogacy leave as well as an increase in UIF and maternity benefits.

“As a multinational organisation, Novartis always strives to meet or exceed statutory requirements in the countries that we operate in. In this instance we realized that extending the parental leave policy to all parents, regardless of gender or whether they gave birth to

their baby or not, will drive our focus on diversity and inclusion that is so important to us at Novartis. This is set to add more value to Novartis families as both parents will have the priceless opportunity to bond with their children in these early formative months.

This policy also strives to make our workplace more inclusive by supporting our employees through the different stages of their lives and empowering them to make the best choices for the health and well-being of their families,” concludes Kadwa.

## **ENDS**

### **Disclaimer**

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

### **About Novartis**

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105 000 people of more than 140 nationalities work at Novartis around the world. Find out more at [www.novartis.com](http://www.novartis.com).

Novartis is on Twitter. Sign up to follow @Novartis at <http://twitter.com/novartis>  
For Novartis multimedia content, please visit [www.novartis.com/news/media-library](http://www.novartis.com/news/media-library)

For questions about the site or required registration, please contact [media.relations@novartis.com](mailto:media.relations@novartis.com)

###

**Novartis Media Relations**

Central media line: +41 61 324 2200  
E-mail: [media.relations@novartis.com](mailto:media.relations@novartis.com)

Sibonile Dube  
Novartis Head of Communications and Public  
Affairs  
+27 66 473 8113 (mobile)  
[sibonile.dube@novartis.com](mailto:sibonile.dube@novartis.com)

Eric Althoff  
Novartis US External Communications  
+1 646 438 4335  
[eric.althoff@novartis.com](mailto:eric.althoff@novartis.com)

**Novartis Investor Relations**

Central investor relations line: +41 61 324 7944  
E-mail: [investor.relations@novartis.com](mailto:investor.relations@novartis.com)

Central		North America	
Samir Shah	+41 61 324 7944	Richard Pulik	+1 862 778 3275
Pierre-Michel Bringer	+41 61 324 1065	Cory Twining	+1 862 778 3258
Thomas Hungerbuehler	+41 61 324 8425		
Isabella Zinck	+41 61 324 7188		